NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
Authors:
- Emma KroezeEKEmma Kroeze
- Lennart A KesterLKLennart A Kester
- Marijn A Scheijde-VermeulenMSMarijn A Scheijde-Vermeulen
- Edwin SonneveldESEdwin Sonneveld
- Melanie M HagleitnerMHMelanie M Hagleitner
- Friederike Ag Meyer-WentrupFMFriederike Ag Meyer-Wentrup
- Margreet A VeeningMVMargreet A Veening
- Auke BeishuizenABAuke Beishuizen
- Jules Pp MeijerinkJMJules Pp Meijerink
- Jan Lc LoeffenJLJan Lc Loeffen
Preprint
Abstract
Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.Keywords
All Related Versions
- Published version: HemaSphere, 8 (7), e117.
This publication has 30 references indexed in Scilit:
- The genomic landscape of pediatric acute lymphoblastic leukemiaNature Genetics, 2022
- Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T‐cell lymphoblastic lymphomaPediatric Blood & Cancer, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsLeukemia, 2022
- Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemiaLaboratory Investigation, 2022
- Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteinsBlood Cancer Journal, 2022
- The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemiaNature Genetics, 2017
- The Canonical Notch Signaling Pathway: Unfolding the Activation MechanismCell, 2009
- CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitorsLeukemia, 2006
- A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemiasLeukemia, 2005
- TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasmsCell, 1991